Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 11/20 | 0.51 |
| ▸ | CYP11B1 | P15538 | 10/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.51 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.51 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.51 |
| ▸ | BRD4 | O60885 | 1/20 | 0.46 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.46 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.46 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.46 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.45 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | DRD1 | P21728 | 1/20 | 0.43 |
| ▸ | DRD5 | P21918 | 1/20 | 0.43 |
| ▸ | DRD3 | P35462 | 1/20 | 0.43 |
| ▸ | SYK | P43405 | 1/20 | 0.43 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19980481 | 0.90 | MAOA (0.49) | CYP11B2CYP11B1CYP1A2CYP19A1CYP17A1 | |
| SCHEMBL6073803 | 0.86 | PBRM1 (0.46) | CYP11B2CYP11B1CYP1A2CYP19A1CYP17A1 | |
| SCHEMBL29846831 | 0.86 | PBRM1 (0.46) | CYP11B2CYP11B1CYP1A2CYP19A1CYP17A1 | |
| SCHEMBL30667271 | 0.84 | PKM (0.49) | TRIM24DRD2DRD1DRD5DRD3 | |
| SCHEMBL8287657 | 0.84 | PKM (0.49) | TRIM24DRD2DRD1DRD5DRD3 | |
| SCHEMBL11255201 | 0.82 | SRD5A1 (0.59) | CYP11B2CYP11B1CYP1A2CYP19A1CYP17A1 | |
| SCHEMBL422074 | 0.80 | SRD5A1 (0.58) | CYP11B2CYP11B1CYP1A2CYP19A1CYP17A1 | |
| SCHEMBL3591114 | 0.79 | CYP11B2 (0.51) | CYP11B2CYP11B1CYP1A2CYP19A1CYP17A1 | |
| SCHEMBL736131 | 0.79 | ATAD2 (0.64) | CYP11B2CYP11B1CYP1A2CYP19A1CYP17A1 | |
| SCHEMBL5543650 | 0.79 | CYP11B2 (0.51) | CYP11B2CYP11B1CYP1A2CYP19A1CYP17A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250282781-A1 | APOL1 INHIBITORS AND METHODS OF USE | HERCULES CAPITAL, INC., AS AGENT | 2025-09-11 | — | — | US | disclosed |
| US-12344610-B2 | APOL1 inhibitors and methods of use | MAZE THERAPEUTICS, INC. (US) | 2025-07-01 | — | — | US | disclosed |
| WO-2024249254-A2 | METHODS OF USING APOL1 INHIBITORS | MAZE THERAPEUTICS, INC. (US) | 2024-12-05 | — | — | WO | disclosed |
| US-20240400565-A1 | APOL1 INHIBITORS AND METHODS OF USE | HERCULES CAPITAL, INC., AS AGENT | 2024-12-05 | — | — | US | disclosed |
| EP-4465982-A2 | APOL1 INHIBITORS AND METHODS OF USE | Maze Therapeutics, Inc. (US) | 2024-11-27 | — | — | EP | disclosed |
| US-11976067-B2 | APOL1 inhibitors and methods of use | MAZE THERAPEUTICS, INC. (US) | 2024-05-07 | — | — | US | disclosed |
| US-20230265096-A1 | APOL1 INHIBITORS AND METHODS OF USE | HERCULES CAPITAL, INC., AS AGENT | 2023-08-24 | — | — | US | disclosed |
| US-20230265096-A1 | APOL1 INHIBITORS AND METHODS OF USE | HERCULES CAPITAL, INC., AS AGENT | 2023-08-24 | — | — | US | disclosed |
| US-20230265096-A1 | APOL1 INHIBITORS AND METHODS OF USE | HERCULES CAPITAL, INC., AS AGENT | 2023-08-24 | — | — | US | disclosed |
| WO-2023141432-A2 | APOL1 INHIBITORS AND METHODS OF USE | MAZE THERAPEUTICS, INC. (US) | 2023-07-27 | — | — | WO | disclosed |
| US-20020052503-A1 | Substituted benzolactam compounds as substance p antagonists | WAKABAYASHI HIROAKI (JP) | 2002-05-02 | — | — | US | disclosed |
| EP-1175417-A1 | SUBSTITUTED BENZOLACTAM COMPOUNDS | Pfizer Products Inc. (US) | 2002-01-30 | — | — | EP | disclosed |
| WO-2001077100-A2 | BENZOAMIDE PIPERIDINE COMPOUNDS AS SUBSTANCE P ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2001-10-18 | — | — | WO | disclosed |
| US-6288225-B1 | Substituted benzolactam compounds as substance P antagonists | PFIZER INC | 2001-09-11 | — | — | US | disclosed |
| EP-0840732-B1 | SUBSTITUTED BENZOLACTAM COMPOUNDS AS SUBSTANCE P ANTAGONISTS | PFIZER (US) | 2001-03-07 | — | — | EP | disclosed |
| US-6180647-B1 | GASTROINTESTINAL DISORDERS; NERVOUS SYSTEM DISORDERS | PFIZER INC. | 2001-01-30 | — | — | US | disclosed |
| WO-2000068224-A1 | SUBSTITUTED BENZOLACTAM COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2000-11-16 | — | — | WO | disclosed |
| EP-0840732-A1 | SUBSTITUTED BENZOLACTAM COMPOUNDS AS SUBSTANCE P ANTAGONISTS | PFIZER INC. (US) | 1998-05-13 | — | — | EP | disclosed |
| WO-1997003066-A1 | SUBSTITUTED BENZOLACTAM COMPOUNDS AS SUBSTANCE P ANTAGONISTS | PFIZER PHARMACEUTICALS INC. (JP) | 1997-01-30 | — | — | WO | disclosed |
| US-4298739-A | ANTICOAGULANTS, ANTIINFLAMMATORY, ANTIULCER, VASODILATOR, PHOSPHODIESTERASE INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1981-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230265096-A1 | APOL1 INHIBITORS AND METHODS OF USE | APOL1, APOB, LDLR | CYP11B2 515/4885CYP11B1 331/4885CYP1A2 1292/4885 |
| US-12344610-B2 | APOL1 inhibitors and methods of use | APOL1, APOB, PON1 | CYP11B2 457/4885CYP11B1 303/4885CYP1A2 1215/4885 |
| US-20020052503-A1 | Substituted benzolactam compounds as substance p antagonists | NPY1R, OPRM1, OPRL1 | CYP11B2 1586/4885CYP11B1 1239/4885CYP1A2 1021/4885 |
| US-11976067-B2 | APOL1 inhibitors and methods of use | APOL1, APOB, LDLR | CYP11B2 515/4885CYP11B1 331/4885CYP1A2 1292/4885 |
| US-20250282781-A1 | APOL1 INHIBITORS AND METHODS OF USE | APOL1, APOB, PON1 | CYP11B2 457/4885CYP11B1 303/4885CYP1A2 1215/4885 |
| US-20240400565-A1 | APOL1 INHIBITORS AND METHODS OF USE | APOL1, APOB, PON1 | CYP11B2 457/4885CYP11B1 303/4885CYP1A2 1215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.